News
SHIEF
0.080
NaN%
--
Shield Therapeutics issues shares under performance plan while keeping other incentive schemes unchanged
TipRanks · 2d ago
Shield Therapeutics issues 2,023,801 shares under retention and performance share plan block listing return
PUBT · 2d ago
Shield Therapeutics Secures Strong Shareholder Backing at 2026 AGM
TipRanks · 06/18 15:27
Shield Therapeutics updates share capital as iron deficiency franchise expands globally
TipRanks · 05/29 08:17
Shield Therapeutics awards CEO new share options to support growth of iron drug franchise
TipRanks · 05/05 06:24
Shield Therapeutics posts profitable Q1 as ACCRUFeR sales surge and CFO departs
TipRanks · 05/01 06:18
Shield Therapeutics Updates Total Voting Rights and Highlights Global Iron Therapy Franchise
TipRanks · 04/30 06:49
Shield Therapeutics Starts Japanese Phase II Trial of ACCRUFeR in Pulmonary Arterial Hypertension
TipRanks · 04/27 06:13
Shield Therapeutics Hits Record ACCRUFeR Sales and Turns Cash-Flow Positive in 2025
TipRanks · 04/09 11:37
Shield Therapeutics Gains Pediatric Boost as Ferric Maltol Data Published in Leading Journal
TipRanks · 04/01 09:52
Shield Therapeutics updates share capital and underscores global iron deficiency franchise
TipRanks · 03/31 08:24
Shield Therapeutics gains EMA backing to extend FeRACCRU use to adolescents
TipRanks · 03/31 06:13
ProKidney appoints Greg Madison as chief commercial officer
TipRanks · 03/25 20:05
ProKidney appoints Greg Madison chief commercial officer; senior leadership team expands
Reuters · 03/25 20:01
Shield Therapeutics Advances ACCRUFeR Into China With NMPA Filing Acceptance
TipRanks · 03/03 07:12
Shield Therapeutics Updates Voting Rights as Iron Drug Expansion Continues
TipRanks · 02/27 07:47
Shield Therapeutics Wins Extra U.S. FDA Exclusivity for ACCRUFeR Pediatric Use
TipRanks · 02/09 07:27
IBM erhält Auftrag zur Unterstützung des SHIELD-Programms der Missile Defense Agency
Reuters · 02/05 14:01
Shield Therapeutics Updates Market on Total Voting Rights and Share Capital
TipRanks · 01/30 08:21
Shield Therapeutics Secures $7.9m China Milestone as ACCRUFeR® Nears NMPA Filing
TipRanks · 01/30 07:32
More
Webull provides a variety of real-time SHIEF stock news. You can receive the latest news about Shield Therapeut through multiple platforms. This information may help you make smarter investment decisions.
About SHIEF
Shield Therapeutics plc is a United Kingdom-based commercial-stage pharmaceutical company. The Company delivers differentiated specialty pharmaceuticals that address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company’s lead product, Accrufer/Feraccru, is broadly indicated for use in adults across multiple therapeutic categories. Ferric maltol is approved in the United States, European Union, the United Kingdom, Canada, Australia and Switzerland for the treatment of iron deficiency with or without anemia in adults. It also has an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialization of ACCRUFeR/FeRACCRU in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. for the Republic of Korea. The Company's subsidiaries include Phosphate Therapeutics Limited, Shield TX (Switzerland) AG, Shield Therapeutics Inc, and Shield TX (UK) Limited.